Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Bode

Showing results (491-500 of 589) with videos related to

Pageof 59
Sort By:
RSC Chemical Biology|June 27, 2022
Chemical synthesis of <i>Torenia</i> plant pollen tube attractant proteins by KAHA ligationNandarapu Kumarswamyreddy, Damodara N Reddy, D Miklos Robkis, et al.
Diabetes, Obesity & Metabolism|August 27, 2014
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metforminJ Reusch, M W Stewart, C M Perkins, et al.
The Diabetes Educator|April 9, 2016
Improving Patient Experience With Insulin Infusion Sets: Practical Guidelines and Future DirectionsAlison B Evert, Bruce W Bode, Bruce A Buckingham, et al.
Diabetes, Obesity & Metabolism|May 19, 2015
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trialS C L Gough, B W Bode, V C Woo, et al.
Scientific Reports|October 11, 2022
Author Correction: Identification, heterologous production and bioactivity of lentinulin A and dendrothelin A, two natural variants of backbone N-methylated peptide macrocycle omphalotin AEmmanuel Matabaro, Hannelore Kaspar, Paul Dahlin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 27, 2024
Development of radiofluorinated MLN-4760 derivatives for PET imaging of the SARS-CoV-2 entry receptor ACE2Jinling Wang, Darja Beyer, Christian Vaccarin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 1994
Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d)D Zhang, I Botos, F X Gomis-Rüth, et al.
Journal of Diabetes Science and Technology|August 25, 2016
Comparison of an Electronic Glycemic Management System Versus Provider-Managed Subcutaneous Basal Bolus Insulin Therapy in the Hospital SettingJoseph Aloi, Bruce W Bode, Jagdeesh Ullal, et al.
Scientific Reports|June 11, 2021
Author Correction: Identifcation, heterologous production and bioactivity of lentinulin A and dendrothelin A, two natural variants of backbone N-methylated peptide macrocycle omphalotin AEmmanuel Matabaro, Hannelore Kaspar, Paul Dahlin, et al.
Structure (London, England : 1993)|November 15, 1996
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug designR A Engh, H Brandstetter, G Sucher, et al.
Pageof 59

Showing results (491-500 of 589) with videos related to

Sort By:
Pageof 59
RSC Chemical Biology|June 27, 2022
Chemical synthesis of <i>Torenia</i> plant pollen tube attractant proteins by KAHA ligationNandarapu Kumarswamyreddy, Damodara N Reddy, D Miklos Robkis, et al.
Diabetes, Obesity & Metabolism|August 27, 2014
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metforminJ Reusch, M W Stewart, C M Perkins, et al.
The Diabetes Educator|April 9, 2016
Improving Patient Experience With Insulin Infusion Sets: Practical Guidelines and Future DirectionsAlison B Evert, Bruce W Bode, Bruce A Buckingham, et al.
Diabetes, Obesity & Metabolism|May 19, 2015
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trialS C L Gough, B W Bode, V C Woo, et al.
Scientific Reports|October 11, 2022
Author Correction: Identification, heterologous production and bioactivity of lentinulin A and dendrothelin A, two natural variants of backbone N-methylated peptide macrocycle omphalotin AEmmanuel Matabaro, Hannelore Kaspar, Paul Dahlin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 27, 2024
Development of radiofluorinated MLN-4760 derivatives for PET imaging of the SARS-CoV-2 entry receptor ACE2Jinling Wang, Darja Beyer, Christian Vaccarin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 1994
Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d)D Zhang, I Botos, F X Gomis-Rüth, et al.
Journal of Diabetes Science and Technology|August 25, 2016
Comparison of an Electronic Glycemic Management System Versus Provider-Managed Subcutaneous Basal Bolus Insulin Therapy in the Hospital SettingJoseph Aloi, Bruce W Bode, Jagdeesh Ullal, et al.
Scientific Reports|June 11, 2021
Author Correction: Identifcation, heterologous production and bioactivity of lentinulin A and dendrothelin A, two natural variants of backbone N-methylated peptide macrocycle omphalotin AEmmanuel Matabaro, Hannelore Kaspar, Paul Dahlin, et al.
Structure (London, England : 1993)|November 15, 1996
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug designR A Engh, H Brandstetter, G Sucher, et al.
Pageof 59